Skip to content
Bethanechol
Myotonachol, Urecholine (bethanechol) is a small molecule pharmaceutical. Bethanechol was first approved as Urecholine on 1982-01-01. It is used to treat drug-induced abnormalities, gastroesophageal reflux, neurogenic urinary bladder, and urinary retention in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M3 and muscarinic acetylcholine receptor M2. In addition, it is known to target muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M1, and muscarinic acetylcholine receptor M5.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
nervous system diseasesD009422
urogenital diseasesD000091642
hereditary congenital and neonatal diseases and abnormalitiesD009358
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bethanechol chloride
Tradename
Company
Number
Date
Products
URECHOLINEOdyssey PharmaceuticalsN-006536 DISCN1982-01-01
5 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bethanechol chlorideANDA2023-05-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
drug-induced abnormalities—D000014—
gastroesophageal refluxEFO_0003948D005764K21
neurogenic urinary bladderHP_0000011D001750N31
urinary retentionHP_0000016D016055R33
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07A: Parasympathomimetics
— N07AB: Choline esters, parasympathomimetics
— N07AB02: Bethanechol
HCPCS
Code
Description
J0520
Injection, bethanechol chloride, myotonachol or urecholine, up to 5 mg
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBETHANECHOL
INN—
Description
Bethanechol is the carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention. It has a role as a muscarinic agonist. It is a quaternary ammonium ion and a carbamate ester.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C[N+](C)(C)C)OC(N)=O
Identifiers
PDB—
CAS-ID674-38-4
RxCUI19257
ChEMBL IDCHEMBL1482
ChEBI ID3084
PubChem CID2370
DrugBankDB01019
UNII ID—
Target
Agency Approved
CHRM3
CHRM3
CHRM2
CHRM2
Organism
Homo sapiens
Gene name
CHRM3
Gene synonyms
NCBI Gene ID
1131
Protein name
muscarinic acetylcholine receptor M3
Protein synonyms
acetylcholine receptor, muscarinic 3, m3 muscarinic receptor
Uniprot ID
Q9HB60
Mouse ortholog
Chrm3 (12671)
muscarinic acetylcholine receptor M3 (Q9ERZ3)
Alternate
CHRM4
CHRM4
CHRM1
CHRM1
CHRM5
CHRM5
Organism
Homo sapiens
Gene name
CHRM4
Gene synonyms
NCBI Gene ID
1132
Protein name
muscarinic acetylcholine receptor M4
Protein synonyms
acetylcholine receptor, muscarinic 4
Uniprot ID
Q4VBK7
Mouse ortholog
Chrm4 (12672)
muscarinic acetylcholine receptor M4 (Q64056)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,773 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details